Abstract
The objective of the present research was to cultivate an oral formulation of an anti-diabetic drug using polymeric nanofiber. A biodegradable polymer i.e. poly (vinyl alcohol) (PVA) nanofiber loaded linagliptin was prepared using electro spinning technique. The drug entrapment in the developed nanofibers was confirmed by scanning electron microscopy and X-ray diraction. The in vivo study was performed on male Wistar rats to establish the pharmacodynamics behavior of developed formulation. The mucoadhesive strength results confirmed that the drug loaded PVA nanofiber patch had the highest mucoadhesion strength compare to PVA film and blank PVA nanofiber, due to its higher water holding capacity and surface area. The in vitro release study suggested that controlled release array of the drug from the nanofiber patch. In vivo activity validated the fact that linagliptin was delivered in its active state and showed visible results when compared to the commercial formulation. Additionally an encapsulation efficacy of 92% of the experimental formulation provides sufficient suggestion that the nanofibers serve as an ideal carrier for the delivery of linagliptin via the sublingual route.
Keywords: Anti-diabetic, nanofibers, polyvinyl alcohol, linagliptin, controlled release.
Current Drug Delivery
Title:Transmucosal Delivery of Linagliptin for the Treatment of Type- 2 Diabetes Mellitus by Ultra-Thin Nanofibers
Volume: 12 Issue: 3
Author(s): Vedant Modgill, Tarun Garg, Amit K. Goyal and Goutam Rath
Affiliation:
Keywords: Anti-diabetic, nanofibers, polyvinyl alcohol, linagliptin, controlled release.
Abstract: The objective of the present research was to cultivate an oral formulation of an anti-diabetic drug using polymeric nanofiber. A biodegradable polymer i.e. poly (vinyl alcohol) (PVA) nanofiber loaded linagliptin was prepared using electro spinning technique. The drug entrapment in the developed nanofibers was confirmed by scanning electron microscopy and X-ray diraction. The in vivo study was performed on male Wistar rats to establish the pharmacodynamics behavior of developed formulation. The mucoadhesive strength results confirmed that the drug loaded PVA nanofiber patch had the highest mucoadhesion strength compare to PVA film and blank PVA nanofiber, due to its higher water holding capacity and surface area. The in vitro release study suggested that controlled release array of the drug from the nanofiber patch. In vivo activity validated the fact that linagliptin was delivered in its active state and showed visible results when compared to the commercial formulation. Additionally an encapsulation efficacy of 92% of the experimental formulation provides sufficient suggestion that the nanofibers serve as an ideal carrier for the delivery of linagliptin via the sublingual route.
Export Options
About this article
Cite this article as:
Modgill Vedant, Garg Tarun, Goyal K. Amit and Rath Goutam, Transmucosal Delivery of Linagliptin for the Treatment of Type- 2 Diabetes Mellitus by Ultra-Thin Nanofibers, Current Drug Delivery 2015; 12 (3) . https://dx.doi.org/10.2174/1567201811666141117144332
DOI https://dx.doi.org/10.2174/1567201811666141117144332 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Goto-kakizaki Rats: Its Suitability as Non-obese Diabetic Animal Model for Spontaneous Type 2 Diabetes Mellitus
Current Diabetes Reviews Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients
Current Alzheimer Research Circulating Cellular Players in Vascular Calcification
Current Pharmaceutical Design miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Current Drug Targets Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a<sup>-/-</sup> Model
Current Pharmaceutical Design Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study
Current Alzheimer Research Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Gene Variation of Endoplasmic Reticulum Aminopeptidase 1 and Risk of Incident Type 2 Diabetes Mellitus amongst 22,718 Initially Healthy Women
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Autonomic Dysfunction in Diabetes: a Consequence of Cardiovascular Damage
Current Diabetes Reviews Predicting Factors Affecting Glucose Monitoring Treatment Satisfaction and Drug Attitude Inventory (Adherence) Among Patients with Type 2 Diabetes Mellitus; Cross-sectional Observational Study
Current Diabetes Reviews Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy
Current Diabetes Reviews Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Niacin Status, NAD Distribution and ADP-Ribose Metabolism
Current Pharmaceutical Design Host Neuro- Immuno-Endocrine Responses In Periodontal Disease
Current Pharmaceutical Design Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Helicase Domain Containing Proteins in Human Disorders
Current Genomics Benzothiazole Derivatives: Novel Inhibitors of Methylglyoxal Mediated Glycation of Proteins In Vitro
Medicinal Chemistry